The Comeback Kid: Science in Sport’s Turnaround & What the Acquisition Means
Let’s cut straight to the chase: 2024 was the year Science in Sport (SiS) stopped flexing in the mirror and started lifting heavier weights. The numbers tell a story of ruthless efficiency, strategic pruning, and a boardroom that’s finally speaking the language of profitability. Oh, and there’s a recommended cash acquisition by bd Capital on the table. Buckle up.
By the Numbers: Less Revenue, More Muscle
At first glance, a 17% revenue drop to £51.9m might raise eyebrows. But here’s the twist: this isn’t a company in retreat—it’s a firm surgically removing dead weight. Consider these gems:
- Gross margin up 250bps to 45.3% – proof they’re squeezing more juice from every pound
- Underlying EBITDA doubling to £4.2m – the kind of growth that makes private equity firms salivate
- Loss per share narrowed from -6.6p to -2.3p – the patient’s vital signs are stabilising
This isn’t accidental. Management has been swinging the cost-cutting axe like a Wimbledon champion:
The Great Margin Makeover
- Chopped 30+ roles (organisational liposuction, if you will)
- Ditched vanity marketing deals that looked good on Instagram but didn’t pay the bills
- Renegotiated supplier terms like a seasoned flea market haggler
The result? A trading contribution margin leap from 20.5% to 26.6%. That’s the financial equivalent of upgrading from a rusty pushbike to a carbon-fibre racing machine.
The bd Capital Play: Strategic Exit or New Era?
The recommended cash acquisition isn’t just a footnote—it’s a full-stop on the turnaround chapter. While details are light (check the Rule 2.7 announcement for the nitty-gritty), this move suggests:
- Shareholder exit ramp: Cash offers often appeal to institutions wanting liquidity
- Private equity appetite: bd Capital likely sees margin expansion potential we mere mortals haven’t fully priced in
- Accelerated growth: The £8.5m equity raise was appetiser; bd might serve the main course
2025 Playbook: Less Hustle, More Precision
Management’s talking about “controlled growth” – corporate speak for “we’re done chasing revenue for vanity metrics”. Watch for:
- Middle East & Australia expansion: Where margins meet growth in sunny climates
- Elite partnerships: British Cycling, GB Aquatics – the kind of sponsorships that turn products into cult items
- PhD’s reinvention: New certifications and product ranges to fight the protein powder wars
The Inventory Tightrope
Stock levels nearly doubled to £9.8m – a calculated gamble. If demand materialises, this is genius foresight. If not, we’re looking at discount bins. But with service levels reportedly improving, the odds look favourable.
Investor’s Lens: Green Shoots or Fool’s Gold?
The turnaround’s real test starts now. That £6m+ in annualised cost savings needs to stick like energy gel to a cyclist’s jersey. Watch these markers:
- Q1 2025 trading updates: Early signs of revenue stabilisation?
- PhD’s revival: Can’t have a two-brand business with one anchor dragging
- Acquisition premium: Will shareholders push for better terms once EBITDA multiples get crunched?
“This isn’t just about surviving—it’s about rewiring the business DNA. The acquisition offer is validation, but the real race starts at the takeover finish line.”
The Bottom Line
Science in Sport has moved from ICU to rehabilitation. The numbers show a company finally marrying its elite branding with commercial pragmatism. Whether through acquisition or continued independence, 2025 looks set to be the year we discover if this phoenix can truly rise from the ashes—or if it’s simply being prepped for someone else’s trophy cabinet.
Food for thought: In the sports nutrition game, margin is king. SiS just proved it can play the monarchy game. The question now – will they rule their domain or bow to new overlords?
